title: Effects of glucosyl hesperidin on serum lipids in hyperlipidemic subjects: preferential reduction in elevated serum triglyceride level.
abstract: Although hesperidin lowers serum total cholesterol (TC) or triglyceride (TG) in animal models, its effect in humans remains unclear. Using a soluble hesperidin derivative, glucosyl hesperidin (G-hesperidin), as a hesperidin source, we examined the efficacy on hyperlipidemic subjects. G-Hesperidin was administered to the subjects at 100 or 500 mg/d for 6 wk. The percentage of subjects who had a change in serum cholesterol levels was less than 20%. However, 45-55% of the total subjects showed a reduction in serum TG level. The subjects were classified into normal (TC<230mg/dL, TG<150mg/dL), high-TC (TC>230 mg/dL, TG<150 mg/dL) and high-TG (TG>150 mg/dL) types. While serum cholesterol levels scarcely changed in any phenotype, TG level was significantly reduced by administration in the high-TG type. In this phenotype, serum apolipoprotein (apo) C-II and E levels decreased by the administration, but non-apo B. G-Hesperidin also raised low-density lipoprotein (LDL)-cholesterol/apo B in the high-TG type. These results indicate that G-hesperidin preferentially lowers serum TG in hypertriglyceridemic subjects and that this effect is possibly caused by the facilitation of catabolism of TG-rich lipoproteins and may contribute to the reduction of small dense LDL.
authors.affiliation: Research and Development Center, Hayashibara Biochemical Laboratories, Inc, 1-2-3 Shimoishii, Okayama 700-0907, Japan.
authors.forename: Yoshikatsu
authors.initials: Y
authors.lastname: Miwa
authors.forename: Mika
authors.initials: M
authors.lastname: Yamada
authors.forename: Takahiro
authors.initials: T
authors.lastname: Sunayama
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Mitsuzumi
authors.forename: Yukari
authors.initials: Y
authors.lastname: Tsuzaki
authors.forename: Hiroto
authors.initials: H
authors.lastname: Chaen
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Mishima
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Kibata
mesh_terms: D000328:Adult; D053304:Apolipoprotein C-II; D001055:Apolipoproteins B / Q000097:blood; D001056:Apolipoproteins C / Q000097:blood; D001057:Apolipoproteins E / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005960:Glucosides / Q000008:administration & dosage*; D006569:Hesperidin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010316:Particle Size; D014280:Triglycerides / Q000097:blood*
chemical_list: D053304:Apolipoprotein C-II; D001055:Apolipoproteins B; D001056:Apolipoproteins C; D001057:Apolipoproteins E; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005960:Glucosides; D008055:Lipids; D014280:Triglycerides; C487382:glucosyl hesperidin; D002784:Cholesterol; D006569:Hesperidin